Tempus AI sued for securities fraud in class action lawsuit

A recent class action lawsuit has been initiated by Pomerantz LLP against Tempus AI, Inc. (NASDAQ: TEM) on the grounds of alleged securities fraud and unlawful business practices. The lawsuit is aimed at investors who acquired Tempus securities within the Class Period, which concluded on August 12, 2025. Those desiring to be part of the class action are advised to reach out to Danielle Peyton via email at [email protected], or call 646-581-9980, provided toll-free. Obtain a copy of the complaint at www.pomerantzlaw.com.

The lawsuit alleges that from August 6, 2024, to May 27, 2025, the Defendants were withholding crucial information from investors. It was not disclosed that Tempus had exaggerated the value of contractual agreements, a significant portion of which were with related entities, encompassed non-binding opt-ins, or were self-financed. Furthermore, the credibility and substance of the collaboration with SoftBank were undermined by the presence of “round-tripping” capital to fabricate revenue for Tempus. Also, the business model of Ambry, which was acquired by Tempus, hinged on assertive and potentially unethical billing practices, posing threats of scrutiny and unsustainability. AstraZeneca had diminished its financial commitments to Tempus through a dubious “pass-through payment” via a joint arrangement among itself, the Company, and Pathos AI. These inconsistencies exposed vulnerabilities in essential operations and revenue outlook, rendering the Defendants’ favorable statements about the Company’s affairs, activities, and future prospects as misleading or devoid of a sound basis.

Investors who encountered losses during the relevant period are urged to contact Danielle Peyton at [email protected] or 646-581-9980 (toll-free) to acquaint themselves with the lawsuit and their prerogatives. No obligations or charges are imposed for participation.